Jonathan W. Goldman

Associate Professor

UCLA

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Indian students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

100%

Pharmacology

80%

Oncology

90%

Targeted Therapy

70%

Tyrosine Kinase

70%

Cancer Therapy

40%

Adjuvant Therapy

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles12

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial

Article Link

Year:

2024

Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

Article Link

Year:

2023

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers

Article Link

Year:

2023

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Article Link

Year:

2023

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Article Link

Year:

2023

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

Article Link

Year:

2023

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

Article Link

Year:

2023

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors

Article Link

Year:

2022

Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial

Article Link

Year:

2022

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib

Article Link

Year:

2022

Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort

Article Link

Year:

2022

Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Article Link

Year:

2022

Collaborators9

Everett E. Vokes

University of Chicago

UNITED STATES

Neil Wenger

Professor

UCLA Health

UNITED STATES

Marina Garassino

Università degli Studi di Torino

ITALY

Terufumi Kato

Chief Physician

Kanagawa Cancer Center

JAPAN

Keunchil Park

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Bartosz Chmielowski

Ronald Reagan UCLA Medical Center

UNITED STATES

Matthias Scheffler

University Hospital Bonn

GERMANY

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES

Katrina Pedersen

Assistant Professor

Washington University in Saint Louis School of Medicine

UNITED STATES

How do Indian students reach out?

Meet Kite AI